Overfilling the bladder made prostate radiotherapy longer and more frustrating
Bladder diameter >10 cm at simulation was associated with longer fractions, more interruptions and greater patient frustration during prostate RT.
Bladder diameter >10 cm at simulation was associated with longer fractions, more interruptions and greater patient frustration during prostate RT.
Patients aged ≥70 reported similar or lower symptom burden, whereas PS ≥2 consistently predicted worse toxicity and slower recovery after radical RT.
Across 14 studies, 9 of 11 anxiety studies and 3 of 5 pain studies reported significant improvement with virtual reality.
In 223 previously irradiated patients, 3×10 Gy and 2×13 Gy salvage HDR brachytherapy produced similar disease control and late toxicity.
Across 52 studies, SGRT-assisted DIBH reduced mean heart dose by 1.21 Gy and LAD dose by 7.05 Gy versus free breathing.
After surgery plus 66–70 Gy, only one of six patients recurred locally, while half developed distant metastases.
Age ≥75 did not independently predict outcomes after proton therapy for HCC, while CCI ≥3 was associated with more than threefold higher mortality.
Across 26 studies, fatal toxicity clustered when BED10 >100 Gy was delivered to the whole tumor with concurrent platinum chemotherapy.
Left-sided breast IMRT was linked to more repolarization changes, while right-sided treatment produced predominantly rhythm abnormalities.
PACTUS 40 Gy/10 produced 30-month median survival in 28 selected frail patients, but incomplete response and toxicity data limit efficacy conclusions.
AI pelvic nodal contours achieved a Dice score of 0.79 on withheld prostate RT cases but retained localized boundary disagreements.
Heart-base-optimized IMRT/VMAT reduced cardiac avoidance area mean dose by about 6 Gy without compromising target coverage.
Diagnostic CT-based VMAT preserved PTV D95 at 99.6% of planned dose across 30 palliative bone RT plans.
Two randomized trials failed to show benefit from brachytherapy-integrated hyperthermia, while inadequate thermal measurement remains a major barrier to clinical validation.
In two PDAC cell lines, measured proton RBE remained near 1.0 through the Bragg peak but rose as high as 6.1 distally.